Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Apr 18, 2013 2:50pm
166 Views
Post# 21271513

RE: RE: Read It Carefully

RE: RE: Read It Carefully

Nexvas, I agree with you 100%. I didn't interpret the press release as revealing anything other than ASSURE dosing is completed. What I find hard to believe is that it will take until the end of June for the topline data to be ready to be released. This trial has been going on for so long now and most were done with dosing and received their final IVUS scan weeks if not months ago.  

 

Really, end of June. I don't believe it. If I'm wrong, we'll be waiting until end of June. But humor me for a bit. Look at these two presentations scheduled for beginning of June:

.

 

May 30 to June 2

National Lipid Association, Las Vegas

https://www.lipid.org/sessions

5/31/13 at 4:50−5:10 PM Transcriptional Regulation of the ApoA-1 Promoter

Norman C.W.Wong,MD, FRCP(C)

.

June 4, European Atherosclerosis Society

Therapeutic options to induce regression of coronary atherosclerosis

Speaker: Steven Nissen

.

Seems like the perfect opportunity for Dr. Wong to present SUSTAIN/ASSURE values for RVX-208 raising apoAI, and HDL-cholesterol. Followed a few days later by Dr. Nissen presenting the Cleveland Clinic's RVX-208 IVUS results. 

 

We will see. GLTA

Bullboard Posts